December 9, 2021 11:00 AM EST
News Briefing

To­tus pulls in $40M Se­ries A with sights on PI3Kα; FDA asks Sesen for an­oth­er tri­al af­ter CRL, biotech says

John Carroll

Editor & Founder

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

Af­ter spend­ing the last 18 months work­ing on iden­ti­fy­ing a lead can­cer drug, biotech start­up To­tus Med­i­cines has now raised

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times